Skip to main content
. 2022 May 9;7(9):e157915. doi: 10.1172/jci.insight.157915

Figure 1. CXCL9 levels in BALF were significantly elevated in responders compared with nonresponders.

Figure 1

Comparison of cytokine levels in (A) BALF and (B) plasma from responders (R; black) and nonresponders (NR; red) before initial nivolumab treatment. Cytokine levels were measured by ELISA and CBA. Data are presented as the mean ± SEM. P values were calculated using the Mann-Whitney U test.